Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are thought to arise from malignant hematopoietic progenitor cells representing early and undifferentiated stem cell clones. In CML there is evidence for a progenitor cell subset free of leukemic clones, depending on the course of the disease. Additionally, it has been suggested that in AML, the early stem cell compartment (CD34 
Introduction
Chronic myeloid leukemia is characterized through the expansion of an early stem cell clone mostly of myeloid origin harboring the Philadelphia (Ph) chromosome. At the molecular level this typical cytogenetic finding represents the translocation t(9;22)(q34;q11) with consecutive gene rearrangement resulting in the chimeric bcr-abl fusion 210 kDa oncoprotein. The course of CML is usually fairly slow in the first phase of the disease but will ultimately progress into an accelerated phase and an overt leukemic state, the blast crisis. Bone marrow or peripheral stem cell transplantation from an HLAidentical sibling or from a matched unrelated donor is the only chance for cure in these patients if they do not respond to treatment with IFN-␣. If such a donor is not available autologous transplantation has been performed in some patients with limited success because of residual leukemic cells in the graft. Different attempts have been made to obtain Ph chromosomenegative autologous graft cells. 1, 2 It has been shown previously that stem cell subpopulations from patients with CML with either CD34-positive/DR-positive or DR-negative phenotype harbor bcr-abl rearrangements in a different manner, depending on the course of the disease. 3 Acute myeloid leukemia is also considered to be an early stem cell disease with fulminant lethal course if untreated. Since only a minority of patients achieve long-term complete remission, bone marrow or stem cell transplantation is still the treatment of choice if appropriate donor cells are available. Specific chromosomal abnormalities can be determined in some FAB subtypes. Furthermore, various gross chromosomal aberrations can be discovered in 60% de novo AML of different subtypes; in secondary AML multiple aberrations occur even more frequently. 5 Therefore, structural chromosome abnormalities can often serve as distinct markers for the malignant cell clone. Interestingly, CD34-positive/CD90-positive or CD34/CD90-negative hematopoietic progenitor cells from patients with AML seem to exhibit different long-term proliferative abilities and different cytogenetic characteristics with regard to the leukemic clone. 6 These recent data offer new aspects for obtaining purged stem cell grafts for autologous transplantation in both diseases.
Early hematopoietic progenitor cells are characterized through their undifferentiated proliferative potential and their expression of CD34 surface antigen. HLA-DR, CD38, c-kit, IL6-receptor and CD90 are also associated with hematopoietic progenitor cells, but not exclusively. The CD90 surface antigen is also expressed on human B and T lymphocytes and neural cells. 7, 8 Cells coexpressing the CD34 and CD90 antigens are thought to be a stem cell subset that contains a high number of long-term culture initiating cells. 9, 10 We sought to investigate the occurrence of malignant clones in different stem cell subsets of patients with CML and AML harboring distinct chromosomal abnormalities. Cells sorted with a fluorescence-activated cell sorter into CD34 +
/CD90
+ and CD34
− fractions were further analyzed cytogenetically with FISH and/or standard cytogenetic techniques. We were unable to detect any cytogenetic difference in CD34-positive progenitor cells of either CD90-positive or CD90-negative phenotype.
Materials and methods

Patients
Blood samples were obtained from patients treated at the Universitätsklinikum Carl Gustav Carus in Dresden after informed consent. We examined blood from 13 patients with CML, two with primary diagnosis (PD), two in early chronic phase (EAP), five in late chronic phase (LCP), five in accelerated phase (AC) and three in blast crisis (BC). Additionally, blood samples were taken from four patients with secondary AML, one patient with de novo AML, one patient with first relapse AML, two patients with ALL, one patient with CMMoL and two healthy donors (Table 1) . Cells were either taken from the leukapheresis product or 20 ml peripheral blood were drawn into heparinized collection tubes and submitted to Lymphoprep (Nycomed, Oslo, Norway) gradient centrifugation according to standard protocols in order to separate a mononuclear cell fraction (MNC).
Cell selection and sorting
Depending on the amount of CD34-positive cells, MNC were either stained directly or further enriched for CD34 engaging the Isolex (Baxter, Unterschleissheim, Germany) or MACS (Miltenyi Biotec, Bergisch Gladbach, Germany) technique. The MNCs or selected cell fractions were stained with fluorochrome-conjugated monoclonal antibodies, CD34-FITC (HPCA-2; Becton Dickinson, Heidelberg, Germany), CD90-PE (F15.42; Coulter Immunotech, Hamburg, Germany) or CD90-PE (5E10; PharMingen, Hamburg, Germany) and isotype controls (679 1Mc7; Coulter Immunotech). Both CD90 antibodies were found to have almost equal staining performances on the sorting instrument. Staining was done for 30 min at 4°C as described by the manufacturer followed by a washing step with phosphate-buffered saline (PBS). After setting adjustments with isotype standard controls, CD34
+ cells were sorted with regard to their CD90 phenotype as shown in Figure 1 . In selected cases purities of the sorted cells proved to be more than 90% (range 90-98%). Cells were sorted on to slides and into culture medium using a fluorescence-activated (FACS Vantage; Becton Dickinson) cell sorter. PBS (phosphatebuffered saline without Ca ++ or Mg ++ ) was used as sheath and sample fluid and cells were air dried in the PBS drop after sorting on to the slide. These stem cell subfractions were further submitted to FISH analysis and/or cytogenetic evaluation, respectively.
Interphase-fluorescence in situ hybridization (I-FISH)
Slides with sorted cells were incubated at room temperature (RT) in 3:1 methanol:acetic acid for 15 min and air-dried. After incubation in hypotonic KCl (0.56%) for 3 min, 2 × saline sodium citrate (pH 7.0) for 2 min and PBS for 3 min and pretreatment with pepsin solution, additional washing (in PBS and PBS-MgCl 2 ), fixation (1% formaldehyde in PBSMgCl 2 ) for 10 min and dehydration procedures (70%, 85% and 100% ethanol), the hybridization was done according to the manufacturer's recommendations. The following DNA probes were used: the LSI bcr/abl translocation probe (VYSIS), the CEP (Chromosome Enumeration DNA FISH Probes) 7 spectrum orange probe (locus D7Z1; VYSIS), the CEP 8 spec-
Figure 1
The dot plot demonstrates the sorting strategy of CD34-FITC (a) and CD90-PE (b) labeled cells from a patient with CML whose blood cells were magnetically preenriched for CD34. Quadrants and sort gates were set according to isotype control antibody staining. trum orange probe (locus D8Z2; VYSIS), the CEP 10 spectrum green probe (specific to bands 10p11.1-q11.1; VYSIS) and the CEP 11 spectrum green probe (locus D11Z1; VYSIS). The CEP 11 probe was used as reference probe to reduce the cut-off value for monosomy 7.
For post-hybridization wash we used the formamide wash procedure. The cells were counterstained with DAPI II (125 ng/ml; VYSIS, Stuttgart, Germany). In order to visualize the bcr (SpectrumGreen) and abl (SpectrumOrange) loci a triple band pass filter set was used. It excites and emits DAPI, rhodamine and fluorescein-type fluorophores. The same filter set was used for investigating the CEP results.
Internal threshold for trisomy was 3% cells showing three signals and for monosomy it was 13% cells showing one signal (done with reference probe). The cut-off value for BCR/ABL positivity in I-FISH was 10.5%.
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Cytogenetics
The FACS-sorted cells were incubated at standard culture conditions for 50 to 94 h in RPMI 1640 glutamax-I (Life Technologies, Karlsruhe, Germany) supplemented with 30% fetal calf serum (Life Technologies), 2.6 l/ml thymidine (ICN Biochemicals, Eschwege, Germany), 10 l/ml gentamycin (10 mg/ml; Life Technologies), 100 U/ml recombinant human (rH) granulocyte colony-stimulating factor (PromoCell, Heidelberg, Germany), 100 U/ml rH granulocyte-macrophage colony-stimulating factor (PromoCell), 100 U/ml rH interleukin-3 (PromoCell), 1 U/ml rH erythropoietin (PromoCell) and 20 ng/ml stem cell factor (PromoCell). Thirty to 53 h to the end of culture time 10 l/ml KaryoMAX colcemid solution (10 g/ml; Life Technologies) was added. Chromosome preparation was done according to classical standard procedures with hypotonic incubation, methanol-acetic acid fixation and Giemsa staining.
Results and discussion
We chose the CD90/Thy1 antigen and the CD34 antigen as candidate surface markers to define a phenotype of early stem cell subsets with distinct proliferative abilities. 9, 10 The amount of CD34/CD90 double positive cells was very low and often undetectable in patients with myeloid malignancies even after pre-enrichment of CD34 cells with magnetic columns. Twelve out of 17 patients with CML and five out of six patients with AML exhibited detectable numbers of CD34
+ cells (mean of 0.75% and 0.65%, respectively). Only one patient suffering from a Ph + pre B-ALL showed 37.5% of CD34/CD90 double positive cells. In two healthy volunteers the number of CD34 +
/CD90
+ was also very low. The percentages and mean/median values of CD90-negative and CD90-positive progenitor cells in the samples examined are depicted in Tables 1 and 2 . The finding of rare Thy-1 expression in acute myeloid leukemia is in keeping with the results from other groups. 6, 12 Successful sorting was accomplished in 17/26 patients for one or both CD90 + and CD90 − fractions. Sort gates were set on the brightest CD90 + cells after isotype standardization as illustrated in Figure 1 . For all kinds of malignancies examined there was no difference in the frequencies of distinct cytogenetic abnormalities in both CD90
+ and CD90 − stem cell subfractions harboring these aberrations in an equal manner. In one patient with CML (No. 4) the percentage of aberrant cells seemed to be low within the CD34 + /CD90 − population (33%), but in this case only three cells were evaluable by FISH analysis so that this result might rather resemble a method bias then a true exception from general findings. Table 3 shows the percentages of detected aberrations within these subpopulations from CML and AML patients and from one patient with pre B-ALL.
If metaphase cytogenetic analysis was employed, aberrations were detected in almost all metaphase nuclei, ie 100% in both progenitor cell subsets. Figure 2 depicts a metaphase karyotype of a sorted stem cell harboring the translocation t (1;3) .
The amount of cytogenetic changes detected with I-FISH analysis was very high: mean 92.2% in the CD90 + fraction and mean 89.2% in the CD90 − fraction. The characteristic appearances of sorted bcr-abl-positive CD34 cells that have been analyzed with FISH technique are shown in Figure 3 . Fusion of the (green) bcr and red (abl) probe results in a bright yellow signal indicating the neighborhood of both loci, ie translocation t(9;22). The blue background color visualizes the DAPI stained interphase nucleus, ie the shape of the cell nucleus after sorting stress, in all cells fluorescence signals were easily detectable and discriminable.
The detection of equally high amounts of cytogenetic aberrations within both CD90-positive and CD90-negative subfractions in patients with AML is in contrast to findings from other groups who describe CD34 + /CD90 + cells as a distinct population with SCID repopulating ability and few cytogenetic changes. 6 However, it should be considered that in different cases of AML (FAB classification, primary or secondary leukemia, first diagnosis or relapse) different stem cell subsets might be affected, so that contrary results about malignancy within the CD34/CD90 subset can be explained with the limited numbers of patient samples in distinct subgroups, and may as well be due to disease definition according to morphological rather than biological features.
Although in early phase CML absence of Ph chromosomepositive cells within the subset of CD34 + /DR − cells has been reported, 3 we could not find any cytogenetic differences between CD90-positive and CD90-negative fractions of CD34 cells in CML of different disease progression stages, in keeping with others. 13, 14 Interestingly, the two CML patients with primary diagnosis seem to have a slight difference in the percentage of bcr-abl-positive cells within the CD90-positive and CD90-negative fractions. It could be assumed that the malignant cell contamination is lower within that CD90-positive fraction in these patients which is in concordance with Verfaille's observations in early phase CML, 3 but that difference is statistically not significant. Many authors describe an overall occurrence of Ph chromosome in different cells and progeni- 
Figure 2
A metaphase analysis of a sorted CD34 cell that harbors the translocation t(1;3) is depicted.
tor cell types from CML patients, occasionally even within the T cell subset. 15, 16 In contrast to these findings, recent data show that in MDS no malignant cell clones are detectable within the CD34
+ pluripotent stem cell fraction. 17 MDS is considered to be a preleukemic state predominantly affecting cells of myeloid origin. About 30% of MDS patients develop an overt leukemia while CML patients ultimately progress into a blast phase. Although in MDS all three hematopoietic lineages show dysplasic features there is now evidence for predomi- nance of malignant clones within the myelomonocytic progenitor subpopulation. 17 It is an interesting observation that the CD90-positive stem cell fraction seems to be completely free of genetically altered cells since the CD90 antigen defines a heterogenous population with enrichment of LTC-IC cells, with committed progenitors still present in this cell population.
These controversial results may reflect the differences in biology of AML, CML and MDS and provide new insights into the diversity of stem cell biology.
We conclude that the CD90 antigen is not an appropriate marker to distinguish benign from malignant blast cells in either CML or AML. The very early hematopoietic progenitor cells are still poorly understood regarding phenotype, regulation of self-renewal, maturation and differentiation. Recent findings indicate different proliferation kinetics even between normal progenitor cells from patients with CML compared to cells from healthy donors. 18 This is probably due to differences in gene expression patterns. 19 The dogma of CD34 antigen positivity of pluripotent stem cells with SCID mouse or sheep in utero repopulating capacity has also been a current focus of controversial discussion. Recent studies suggest the existence of a subset of cells with long-term culture initiating potential with a CD34-negative/lineage-negative phenotype. [20] [21] [22] Nevertheless, purified CD34 cells reconstitute hematopoiesis rapidly and reliably.
2,10 Detection of additional surface markers [23] [24] [25] or distinct biological precursor cell features 22 is required to define progenitor cell subpopulations with distinct properties so that cell sorting strategies can be applied to patients with leukemic diseases with therapeutic intent.
